| 0 (0%) | 11-14 13:53 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 18.1 | 1-year : | 21.14 |
| Resists | First : | 15.5 | Second : | 18.1 |
| Pivot price | 12.94 |
|||
| Supports | First : | 12.28 | Second : | 10.3 |
| MAs | MA(5) : | 14.12 |
MA(20) : | 12.69 |
| MA(100) : | 12.1 |
MA(250) : | 12.09 |
|
| MACD | MACD : | 0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 84.9 |
D(3) : | 82.1 |
| RSI | RSI(14): 58.6 |
|||
| 52-week | High : | 28.68 | Low : | 4.9 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ FBRX ] has closed below upper band by 18.6%. Bollinger Bands are 41.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 14.68 - 14.76 | 14.76 - 14.8 |
| Low: | 13.59 - 13.68 | 13.68 - 13.74 |
| Close: | 13.7 - 13.85 | 13.85 - 13.94 |
Fri, 14 Nov 2025
FBRX: Net loss widened as R&D spending surged; FB102 clinical trials advance with strong cash position - TradingView
Fri, 14 Nov 2025
Forte Biosciences (NASDAQ: FBRX) expects 3 FB102 readouts in 2026 after IND opens - Stock Titan
Thu, 13 Nov 2025
Why FBRX stock attracts global investors - Quarterly Portfolio Review & Expert Curated Trade Setup Alerts - newser.com
Thu, 13 Nov 2025
Is FBRX stock positioned for long term growth - 2025 Technical Overview & Technical Buy Zone Confirmation - newser.com
Thu, 13 Nov 2025
Is FBRX stock poised for growth - Weekly Market Summary & Stock Market Timing Techniques - newser.com
Thu, 13 Nov 2025
Is FBRX trending in predictive chart models - July 2025 Fed Impact & Consistent Profit Alerts - newser.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 12 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 4.9 (%) |
| Held by Institutions | 86.6 (%) |
| Shares Short | 261 (K) |
| Shares Short P.Month | 113 (K) |
| EPS | -3.69 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.02 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -40.8 % |
| Return on Equity (ttm) | -73.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.52 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -39 (M) |
| Levered Free Cash Flow | -23 (M) |
| PE Ratio | -3.97 |
| PEG Ratio | 0 |
| Price to Book value | 1.81 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.71 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|